Phosphotyrosine-containing protein (pTyr protein) (pTyr protein)

Phosphotyrosine-containing proteins are a diverse group of proteins characterized by the covalent attachment of a phosphate group to one or more tyrosine residues, a post-translational modification mediated by protein tyrosine kinases (PTKs) (Source: UniProt). This modification serves as a fundamental regulatory mechanism in eukaryotic cells, acting as a molecular switch that controls signal transduction pathways involved in growth, differentiation, and metabolism (Source: PubMed, PMID: 12077346). The presence of a phosphotyrosine (pTyr) residue often creates a specific docking site for proteins containing Src Homology 2 (SH2) or Phosphotyrosine-Binding (PTB) domains, allowing for the rapid assembly of signaling complexes in response to extracellular stimuli (Source: NIH, National Cancer Institute). Dysregulation of tyrosine phosphorylation, such as the constitutive activation of kinases like BCR-ABL or EGFR, is a primary driver of many human cancers and inflammatory diseases (Source: PubMed, PMID: 15526087). Consequently, these proteins and the enzymes that regulate them are major targets for therapeutic intervention, with numerous small molecule inhibitors and monoclonal antibodies currently in clinical use (Source: PubChem). Monitoring the phosphorylation status of specific proteins within this class is also a critical component of precision medicine, serving as a biomarker for both disease diagnosis and the assessment of therapeutic efficacy (Source: Nature Reviews Cancer).

Other names

Tyrosine-phosphorylated proteinpTyr-proteinPhosphotyrosine proteinPhospho-tyrosine protein

Drugs typically modulate the levels of phosphotyrosine-containing proteins by inhibiting protein tyrosine kinases (PTKs), which are the enzymes responsible for the phosphorylation of tyrosine residues. By blocking the ATP-binding site or the substrate-binding site of these kinases, drugs prevent the formation of the phosphotyrosine modification, thereby disrupting downstream oncogenic or inflammatory signaling pathways. Alternatively, some therapeutic approaches aim to inhibit protein tyrosine phosphatases (PTPs) to maintain phosphorylation levels in specific contexts, or use SH2-domain mimetics to block the recognition of pTyr residues by effector proteins.